HIPEC FOR OVARIAN CANCER
THE OVHIPEC TRIAL AND CURRENT EVIDENCE

Before OVHIPEC, advanced ovarian cancer treatment had improved primarily through surgical debulking and platinum-based chemotherapy — but durable cures remained rare. OVHIPEC was the first phase III randomised trial to demonstrate clear overall survival benefit from adding HIPEC to standard care, transforming the modern conversation about locoregional therapy in ovarian cancer.

“OVHIPEC is currently the only phase III randomised trial in HIPEC oncology to show a 12-month absolute median survival gain — making it the strongest evidence base in the entire HIPEC literature.”

• The Pre-OVHIPEC Treatment Standard

  Standard treatment for stage III/IV ovarian cancer is neoadjuvant carboplatin + paclitaxel followed by interval cytoreductive surgery, then completion of systemic chemotherapy. Five-year survival remains around 30–40%. Recurrence on the peritoneal surface is the dominant pattern of failure.

• The Biological Logic

  Ovarian cancer spreads predominantly along peritoneal surfaces — exactly where direct cavity drug delivery and heat sensitisation have their greatest effect. Cisplatin's chemo-heat synergy is among the strongest of any drug. Combining the right cancer biology with the right drug at the right delivery site was the OVHIPEC hypothesis.

Conducted by Willemien van Driel and the Dutch OVHIPEC investigators, the trial was published in The New England Journal of Medicine in January 2018 with subsequent long-term updates confirming sustained survival benefit.

• Multi-Centre Dutch Phase III RCT

  245 patients with newly diagnosed stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomised across 8 Dutch centres between 2007 and 2016. The trial focused on patients with disease too extensive for upfront optimal cytoreduction — i.e., patients receiving neoadjuvant chemotherapy followed by interval debulking.

• Eligibility: Stage III, Responding to Neoadjuvant Therapy

  All patients received 3 cycles of carboplatin + paclitaxel before randomisation. Patients had to show stable or responding disease on neoadjuvant chemotherapy, with disease judged at least potentially completely resectable at interval debulking.

• Treatment Arms: Interval Surgery vs Interval Surgery + HIPEC

  The control arm received interval cytoreductive surgery alone, followed by 3 more cycles of carboplatin + paclitaxel. The experimental arm received the same interval surgery plus immediate HIPEC with cisplatin 100 mg/m² heated to 40°C for 90 minutes, followed by the same 3 cycles of completion chemotherapy.

• Primary Endpoint: Recurrence-Free Survival

  The pre-specified primary outcome was recurrence-free survival (RFS) — time from randomisation to disease recurrence or death. Secondary endpoints included overall survival, surgical complications, and quality of life.

• Long-Term Update Confirmed Sustained Benefit

  Subsequent extended follow-up (Aronson et al, Lancet Oncology 2023) confirmed sustained benefit at 10 years. Both RFS and OS advantages persisted, supporting the durability of the HIPEC effect when delivered at the right point in the treatment course.

Headline outcomes from the primary publication and long-term follow-up.

OVHIPEC enrolled a specific population — stage III ovarian cancer responding to neoadjuvant chemotherapy and undergoing interval debulking. Translating the trial into clinical practice requires understanding which patients match the trial population.

• Strong Candidates Match the OVHIPEC Population

  Stage III epithelial ovarian, fallopian tube, or primary peritoneal cancer. Disease initially too extensive for optimal upfront cytoreduction, undergoing neoadjuvant carboplatin + paclitaxel with response, and proceeding to interval cytoreductive surgery with reasonable expectation of complete cytoreduction (CC-0 or CC-1).

• Uncertain Role: Front-Line Optimal Surgery

  Patients who undergo upfront optimal cytoreduction (no neoadjuvant chemotherapy) were not represented in OVHIPEC. The benefit of adding HIPEC to primary debulking surgery is being studied in trials like HORSE and CHIPOR but is not yet established.

• Recurrent Ovarian Cancer

  HIPEC at secondary cytoreduction for platinum-sensitive recurrent ovarian cancer is supported by some series but lacks definitive phase III evidence comparable to OVHIPEC. Selected patients at experienced centres may benefit, particularly those with limited disease and good performance status.

• BRCA Mutation Considerations

  OVHIPEC analyses suggested benefit was consistent regardless of BRCA status. However, BRCA-mutated patients now have multiple effective options (PARP inhibitors, platinum-based therapy), and treatment sequencing should be discussed with a gynaecologic oncologist. HIPEC and PARP inhibitors can be complementary rather than alternative strategies.

Modern clinical scenarios where HIPEC is considered alongside standard ovarian cancer therapy.

The complete journey for a stage III ovarian cancer patient receiving HIPEC at interval debulking.

1. 1

   Step 1: Diagnosis, Staging, and Neoadjuvant Planning

   Surgical staging (laparoscopy or imaging), histology confirmation, BRCA testing, and assessment of upfront resectability. Patients with disease unsuitable for primary cytoreduction proceed to neoadjuvant chemotherapy.

2. 2

   Step 2: Neoadjuvant Chemotherapy (3 Cycles)

   Three cycles of carboplatin + paclitaxel delivered every 3 weeks. Response is monitored with imaging and CA-125 levels. Most patients show meaningful tumour reduction.

3. 3

   Step 3: Restaging and Multi-Disciplinary Review

   CT or MRI restaging confirms response and feasibility of interval debulking. Gynaecologic oncology MDT confirms the case for adding HIPEC based on OVHIPEC criteria.

4. 4

   Step 4: Interval Cytoreductive Surgery + HIPEC

   Single OR session: cytoreductive surgery (hysterectomy, BSO, omentectomy, peritonectomy as required) followed by HIPEC with cisplatin 100 mg/m² at 40°C for 90 minutes.

5. 5

   Step 5: Recovery and Completion Chemotherapy

   7–14 days inpatient including ICU. After surgical recovery (4–6 weeks), patients complete 3 additional cycles of carboplatin + paclitaxel and begin PARP inhibitor maintenance if BRCA-mutated or HRD-positive.

Explore the full hyperthermia knowledge base.

Frequently Asked Questions

Common questions about HIPEC for ovarian cancer.